熱門資訊> 正文
葛兰素史克结束与IDEAYA就两名候选人进行合作
2025-12-06 06:04
- GSK (GSK) is terminating a collaboration and licensing agreement with IDEAYA Biosciences (IDYA) for two of the latter's assets.
- The 2020 pact covers the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs, both under investigation to treat solid tumors.
- The two programs utilize synthetic lethality, a relatively new field in oncology treatments involving genetic interaction where the combination of two genetic events results in cell death or death of an organism.
- The agreement called for IDEAYA to receive US profit share and ex-US royalties for both candidates. IDEAYA also received a $100M upfront payment.
More on IDEAYA Biosciences
- IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away
- IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
- Seeking Alpha’s Quant Rating on IDEAYA Biosciences
- Historical earnings data for IDEAYA Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
